EUCTR2008-003779-37-DE进行中（未招募）不适用
Capecitabine and bevacizumab ± vinorelbine as 1st line treatment in HER2/neu-negative metastatic or locally advanced inoperable breast cancer patients - CARIN-Trial
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- iOMEDICO AG
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •-Histologically or cytologically confirmed HER2-negative, adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease, who are candidates for chemotherapy
- •-effective, non-hormonal means of contraception during the study and for a period of 6 months following the last administration of study drug
- •- Adequate hepatic and renal function
- •- Adequate hematologic function
- •- Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- contra-indication against Capecitabine, Bevacizumab or Vinorelbin
- •- Previous chemotherapy or previous bevacizumab-therapy for metastatic or locally recurrent breast cancer
- •-Other primary tumors within the last 5 years, except for adequately controlled limited basal cell carcinoma of the skin, or carcinoma in situ of the cervix.
- •- Pregnant or lactating women
- •- Participation in other clinical trials within 4 weeks prior to randomization
研究者
相似试验
进行中（未招募）
不适用
VINORELBINE AND CAPECITABINE as first line treatment in advanced breast cancer patients with non measurable lesions for RECIST criteria - VNBCAPmetastatic breast cancerEUCTR2005-005680-29-ITAZIENDA OSPEDALIERA S. LUIGI GONZAGA100
已完成
3 期
Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast CancerMetastatic Breast CancerNCT00868634iOMEDICO AG600
进行中（未招募）
不适用
Adjunction with Capecitabin, Lapatinib and Vinorelbin to treat patients with HER2/new-positive, advanced or metastized breast cancer after failure of TrastuzumabFemale patients with HER2/new-positive, locally advanced or metastized breast cancer after failure of chemotherapy with TrastuzumabMedDRA version: 15.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017219-13-DEDeutsche Krebsgesellschaft Sponsor GmbH
进行中（未招募）
不适用
Sorafenib and Bevacizumab as first- line treatment in patients with advanced renal cell carcinomaPatients with advanced renal cell carcinomaEUCTR2006-002851-33-ATniv. Prof. Dr. Manuela Schmidinger
已完成
2 期
A phase ll study of Capecitabine plus Bevacizumab therapy for advanced/recurrent colo-rectal cancer with difficulty on intensive chemotherapy (OGSG 1102)colo-rectal cancerJPRN-UMIN000005209Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)30